[1]
|
鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274.
|
[2]
|
European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398.
|
[3]
|
Kim, J.H., Sinn, D.H., Kang, W., et al. (2017) Low-Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Re-ceiving Entecavir Treatment. Hepatology, 66, 335-343. https://doi.org/10.1002/hep.28916
|
[4]
|
尤红, 王福生, 李太生, 孙亚朦, 徐小元, 贾继东, 南月敏, 王贵强, 侯金林, 魏来, 段钟平, 庄辉. 慢性乙型肝炎防治指南(2022年版) [J]. 传染病信息, 2023, 36(1): 1-17.
|
[5]
|
Xing, M., Sen, L., Jane, D. and Andrew, G.I. (2020) Chronic Hepatitis B Management in Clinical Practice in Fuzhou Province, China: Retrospective Cross-Sectional Analysis of Electronic Medical Record Data. Hepatology International, 14, 1-470. https://doi.org/10.1007/s12072-020-10030-4
|
[6]
|
王健, 吴东洋, 郑建兴, 张金凤, 王利民. 恩替卡韦治疗HBeAg阳性慢性乙型肝炎抗病 效应评估[J]. 中华医院感染学杂志, 2023, 33(5): 652-656.
|
[7]
|
Haché, C. and Villeneuve, J.P. (2006) Lamivudine Treatment in Patients with Chronic Hepatitis B and Cirrhosis. Expert Opinion on Pharmacotherapy, 7, Article ID: 183543. https://doi.org/10.1517/14656566.7.13.1835
|
[8]
|
Manns, M.P., Akarca, U.S., Chang, T.T., et al. (2012) Long-Term Safety and Tolerability of Entecavir in Patients with Chronic Hepatitis B in the Rollover Study ETV-901. Ex-pert Opinion on Drug Safety, 11, 361-368.
https://doi.org/10.1517/14740338.2012.653340
|
[9]
|
Sun, Y., Wu, X., Zhou, J., et al. (2020) Persistent Low-Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepatology, 18, 2582-2591. https://doi.org/10.1016/j.cgh.2020.03.001
|
[10]
|
陈贺, 傅涓涓, 李丽, 等. 长期恩替卡韦经治慢性乙型肝炎患者低病毒血症的相关影响因素[J]. 临床肝胆病杂志, 2021, 37(3): 556-559.
|
[11]
|
Agarwal, K., Brunetto, M., Seto, W.K., et al. (2018) 96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection. Journal of Hepatology, 68, 672-681.
https://doi.org/10.1016/j.jhep.2017.11.039
|
[12]
|
Chen, X.Y., Ren, S., Lu, J., et al. (2022) Combination Therapy in HBeAg-Negative Chronic Hepatitis B Patients with Low-Level Viremia to Nucleos (Tide) Analogues [c]. EASL, Ab-stracts (SAT382), London.
|
[13]
|
孙亚朦, 贾继东, 尤红. 2022年《扩大慢性乙型肝炎抗病毒治疗的专家意见》解读[J]. 中国临床医生杂志, 2022, 50(10): 1144-1146.
|
[14]
|
Zhang, S., Zhang, X., Jin, H., Dou, Y., Li, L., Yuan, X., Dong, C., Hou, M., Nan, Y.M. and Shang, J. (2023) Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 11, 67-75.
|
[15]
|
宣碧碧, 徐永红, 杜忠彩, 刘玉, 杨玉玲, 边城. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系[J]. 临床肝胆病杂志, 2022, 38(10): 2252-2259.
|
[16]
|
Lee, S.B., Jeong, J., Park, J.H., Jung, S.W., Jeong, I.D., Bang, S.J., et al. (2020) Low-Level Viremia and Cirrhotic Complications in Patients with Chronic Hepatitis B According to Adherence to Entecavir. Clinical and Molecular Hepatology, 26, 364-375. https://doi.org/10.3350/cmh.2020.0012
|
[17]
|
周洪波, 刘丹阳, 吕丹, 袁立红. 不同核苷酸类药物治疗慢性乙型病毒性肝炎患者的临床效果[J]. 中国药物经济学, 2021, 16(8): 51-54.
|
[18]
|
Yim, H.J., Kim, I.H., Suh, S.J., Jung, Y.K., Kim, J.H., Seo, Y.S., et al. (2018) Switching to Tenofovir vs Continuing Entecavir for Hepatitis B Virus with Par-tial Virologic Response to Entecavir: A Randomized Controlled Trial. Journal of Viral Hepatitis, 25, 1321-1330. https://doi.org/10.1111/jvh.12934
|
[19]
|
Papatheodoridis, G.V., Manesis, E.K., Manolakopoulos, S., Elefsiniotis, I.S., Goulis, J., Giannousis, J., et al. (2008) Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic Hepatitis B Virus Infection? Hepatology, 48, 1451-1459. https://doi.org/10.1002/hep.22518
|
[20]
|
Zhang, Q., Peng, H., Liu, X., Wang, H., Du, J., Luo, X., et al. (2021) Chronic Hepatitis B Infection with Low-Level Viremia Correlates with the Progression of the Liver Disease. Journal of Clinical and Translational Hepatology, 9, 850-859. https://doi.org/10.14218/JCTH.2021.00046
|
[21]
|
陈词. 罗新华: 慢乙肝合并脂肪肝的抗病毒治疗及预后[J]. 肝博士, 2019(4): 26-27.
|
[22]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84.
https://doi.org/10.1002/hep.28431
|
[23]
|
Machado, M.V., Oliveira, A.G. and Cortez-Pinto, H. (2011) Hepatic Stea-tosis in Hepatitis B Virus Infected Patients: Meta-Analysis of Risk Factors and Comparison with Hepatitis C Infected Pa-tients. Journal of Gastroenterology and Hepatology, 26, 1361-1367. https://doi.org/10.1111/j.1440-1746.2011.06801.x
|
[24]
|
Hui, R.W.H., Seto, W.K., Cheung, K.S., et al. (2018) In-verse Relationship between Hepatic Steatosis and Hepatitis B Viremia: Results of a Large Case-Control Study. Journal of Viral Hepatitis, 25, 97-104.
https://doi.org/10.1111/jvh.12766
|
[25]
|
Minakari, M., Molaei, M., Shalmani, H.M., et al. (2009) Liver Steatosis in Patients with Chronic Hepatitis B Infection: Host and Viral Risk Factors. European Journal of Gastroenterology & Hepatology, 21, 512-516.
https://doi.org/10.1097/MEG.0b013e328326792e
|
[26]
|
Mak, L.Y., Hui, R.W., Fung, J., et al. (2020) Diverse Ef-fects of Hepatic Steatosis on Fibrosis Progression and Functional Cure in Virologically Quiescent Chronic Hepatitis B. Journal of Hepatology, 73, 800-806.
https://doi.org/10.1016/j.jhep.2020.05.040
|
[27]
|
Ya, M.S., Xiao, N.W., Jia, L.Z. and Tong, T. (2020) Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepa-tology, 18, 2582-2591.e6.
https://doi.org/10.1016/j.cgh.2020.03.001
|
[28]
|
叶晓晓, 杨海飞, 张赛君. 不同HBV DNA载量慢性乙型肝炎患儿肝脏病理肝功能及血纤维化指标变化对照研究[J]. 中国妇幼保健, 2021, 36(8): 1790-1792.
|
[29]
|
Kim, J.H. and Sinn, D.H. (2020) Low-Level Viremia in Patients Undergoing Antiviral Therapy: Does It Indicate Time for a Change? Clinical and Molecular Hepatology, 26, 315-317. https://doi.org/10.3350/cmh.2020.0084
|
[30]
|
Burns, G.S. and Thompson, A.J. (2014) Viral Hepatitis B: Clinical and Epidemiological Characteristics. Cold Spring Harbor Perspectives in Medicine, 4, a024935. https://doi.org/10.1101/cshperspect.a024935
|
[31]
|
Yenilmez, E., Çetinkaya, R.A. and Tural, E. (2018) Diagnostic Dilemma for Low Viremia with Significant Fibrosis; Is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage? Balkan Medical Journal, 35, 326-332. https://doi.org/10.4274/balkanmedj.2017.0888
|